Melin­ta Ther­a­peu­tics nabs FDA nod for more con­ve­nient re­work of an­tibi­ot­ic Or­bac­tiv, a for­mer Eli Lil­ly can­di­date

As pres­sure ris­es to ad­dress the su­per­bug cri­sis, Melin­ta Ther­a­peu­tics says it now has a more con­ve­nient op­tion to treat those with an­tibi­ot­ic-re­sis­tant skin in­fec­tions.

Melin­ta got the OK for a new-and-im­proved for­mu­la­tion of its an­tibi­ot­ic ori­ta­vancin in acute bac­te­r­i­al skin and skin struc­ture in­fec­tions (AB­SS­SI) caused by sus­cep­ti­ble iso­lates of Gram-pos­i­tive mi­croor­gan­isms, in­clud­ing MR­SA, the com­pa­ny an­nounced on Mon­day. The drug, mar­ket­ed as Kimyr­sa, can be ad­min­is­tered over one hour as op­posed to Melin­ta’s ear­li­er Or­bac­tiv, which takes three.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER